


Product data sheet



MedKoo Cat#: 559120 Name: L-365260 CAS: 118101-09-0 Chemical Formula: C ₂₄ H ₂₂ N ₄ O ₂ Exact Mass: 398.1743 Molecular Weight: 398.466	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:

L-365260 is a selective cholecystinin receptor 2 (CCK2) antagonist (IC₅₀ values are 2 and 280 nM at CCK2 and CCK1 receptors respectively).

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	39.85	100.0
Ethanol	39.85	100.0

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.51 mL	12.55 mL	25.10 mL
5 mM	0.50 mL	2.51 mL	5.02 mL
10 mM	0.25 mL	1.26 mL	2.51 mL
50 mM	0.05 mL	0.25 mL	0.50 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

1. Chung L, Moore SD, Cox CL. Cholecystinin action on layer 6b neurons in somatosensory cortex. *Brain Res.* 2009 Jul 28;1282:10-9. doi: 10.1016/j.brainres.2009.05.061. Epub 2009 Jun 2. PMID: 19497313; PMCID: PMC2738607.

In vivo study

1. Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. *Eur J Pharmacol.* 1990 Jan 25;176(1):35-44. doi: 10.1016/0014-2999(90)90129-t. PMID: 2311658.

2. Lotti VJ, Chang RS. A new potent and selective non-peptide gastrin antagonist and brain cholecystinin receptor (CCK-B) ligand: L-365,260. *Eur J Pharmacol.* 1989 Mar 21;162(2):273-80. doi: 10.1016/0014-2999(89)90290-2. PMID: 2721567.

7. Bioactivity

Biological target:

L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystinin receptor (CCK-B), with K_s of 1.9 nM and 2.0 nM, respectively.

Product data sheet



In vitro activity

The excitatory actions of CCK8S were mimicked by the selective CCK(B) receptor agonist CCK4, and attenuated by the selective CCK(B) receptor antagonist L365260, indicating a role for CCK(B) receptors.

Reference: Brain Res. 2009 Jul 28;1282:10-9. <https://pubmed.ncbi.nlm.nih.gov/19497313/>

In vivo activity

Rats injected twice daily for 6 days with incremental doses of morphine became tolerant to the analgesic effects of the drug. Twice daily injections of either 8 mg/kg L-365,031 or 0.2 mg/kg L-365,260 prevented the development of tolerance to morphine analgesia.

Reference: Eur J Pharmacol. 1990 Jan 25;176(1):35-44. <https://pubmed.ncbi.nlm.nih.gov/2311658/>

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.